Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...
Get seamless access to Morningstar data and the flexibility to use it in your favorite coding environments with the morningstar_data Python package. This new way to experience Direct lets you save ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback